Life Biosciences is a privately held company tracked for investment-relevant business and technology developments.
This slot renders the company's funding history: dates, rounds, amounts, valuations and lead investors once populated in data/funding-rounds.json.
Life Biosciences has dosed 18 patients with ER100 (three Yamanaka factors via viral vector) targeting retinal disease; primate studies showed reversal of glaucoma and NION disease; if successful, the platform should work across all organ systems.